EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases
Sirakoss Receives CE Mark For Osteo3 Synthetic Bone Graft Substitute
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the
Epidarex Expands Team
We are pleased to welcome Terri Burke to the Epidarex team. Terri joins the Epidarex transatlantic team as a Venture Partner and will focus on
It’s Good Business Sense for Charities to be Sustainable – Commentary by Epidarex’s Sinclair Dunlop as Featured in The Times
The following article was published in The Times on December 26, 2018 Mention the word “charity” to most people and they’ll think of the grey-haired
IGEM Therapeutics Announces Final Close of £5 million Series A Financing Round
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel
Edinburgh Molecular Imaging Appoints Bernhard Sixt as New Chief Executive Officer
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular
Edinburgh Molecular Imaging Ltd Appoints New Chairman
Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology
NodThera Announces the Appointment of Alison Strutt PhD as Head of Finance & Operations, the Launch of its New Corporate Office in Boston and the Opening of its Laboratory in Seattle
Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to